A 83016A
Latest Information Update: 21 May 2001
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 21 May 2001 Profile reviewed but no significant changes made
- 16 Jan 1995 No-Development-Reported for Bacterial infections in USA (Unknown route)